The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Zepbound (tirzepatide) as the first prescription medication for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
OSA is a sleep disorder characterized by repeated interruptions in breathing during sleep, leading to reduced oxygen levels and disrupted rest. Traditionally, treatments have focused on lifestyle changes and the use of devices like Continuous Positive Airway Pressure (CPAP) machines. Zepbound offers a pharmacological alternative by addressing the condition’s underlying factors, particularly excess weight, which is a significant risk factor for OSA.
Zepbound is administered via subcutaneous injection and is also approved for weight management in adults with obesity. Its dual benefits in weight reduction and OSA treatment position it as a valuable option for individuals struggling with both conditions.
The FDA’s approval of Zepbound marks a significant advancement in the treatment of OSA, providing a new therapeutic option for patients and healthcare providers.
Leave a Reply